Merck (MRK) Cash & Current Investments (2009 - 2026)

Merck (MRK) has reported Cash & Current Investments for 18 consecutive years, with $7.1 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Current Investments fell 17.18% year-over-year to $7.1 billion in Q2 2026; TTM through Jun 2026 was $7.1 billion, a 17.18% decrease from a year earlier, with the FY2025 full-year figure at $14.6 billion, up 6.4% from the prior year.
• Cash & Current Investments was $7.1 billion for Q2 2026 at Merck, up from $5.7 billion in the prior quarter.
• Over five years, Cash & Current Investments peaked at $18.2 billion in Q3 2025 and troughed at $5.6 billion in Q1 2024.
• A 5-year average of $10.3 billion and a median of $9.7 billion in 2022 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments slumped 46.23% in 2023 and soared 92.99% in 2024, its largest moves.
• Over 5 years, Cash & Current Investments stood at $13.2 billion in 2022, then tumbled by 46.23% to $7.1 billion in 2023, then surged by 92.99% to $13.7 billion in 2024, then advanced by 6.4% to $14.6 billion in 2025, then tumbled by 50.97% to $7.1 billion in 2026.
• The last three Cash & Current Investments figures came in at $7.1 billion (Q2 2026), $5.7 billion (Q1 2026), and $14.6 billion (Q4 2025), per Business Quant data.